In a research report issued Friday, J.P.
Analysts are weighing in on two biotechnology companies Keryx Pharmaceutical (NASDAQ:KERX) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT), with mixed ratings. Keryx Pharmaceutical BTIG analyst Hartaj Singh came out with a …
BTIG analyst Hartaj Singh weighed in today with a pessimistic view on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company announced that its lead candidate Aurxyia (Fexeric in the …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while reducing the …
Keryx Biopharmaceuticals (NASDAQ:KERX) rose more than 12% in pre-market trading up to $4.40 after this morning’s announcement that the company received approval in Europe …
Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the European Commission has approved Fexeric® (ferric citrate coordination complex) for the control of elevated serum phosphorus levels, or …
In a research report published Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) with a $22 …
Recently, various executives have taken part in insider selling activity for the stocks of Keryx Biopharmaceuticals (NASDAQ:KERX), Facebook Inc (NASDAQ:FB), Celgene Corporation (NASDAQ:CELG), and Illumina, Inc. (NASDAQ:ILMN).
GoPro Inc (NASDAQ:GPRO) shares are up 2.35% in pre-market trading to $58.
MannKind Corporation (NASDAQ:MNKD) shares spiked 6.28% in pre-market trading to $4.
